Money on the markets
A maturing market amid the mayhem
Orchid Chemicals dives
Email 
Print
Shares in Orchid Chemicals hit a 52-week high in early trades on the sale of its key generic injectable business but ended 10.35 percent lower at 197.85 rupees on Wednesday after growth concerns sparked a sell-off.
Orchid Chemicals remained one of the top traded stocks on BSE ending with a volume of over 9.5 million shares.
Late on Tuesday, U.S.-based Hospira Inc said it would buy Orchid Chemicals & Pharmaceuticals Ltd’s generic injectable business for $400 million, in a deal that would expand its global reach and position as the market leader.
Orchid Chemicals expects the sale of its generic injectable drug to add 7-8 rupees a share to its earnings in FY11, Managing Director K Raghavendra Rao said.
Do you think the counter makes a good buy at current valuation?
Post Your Comment
-
Author Profile
-
- Ireland rejects blame for Apple's low tax rate
- Rupee falls to near six-month low on stock losses, importer demand
- iGate sacks Murthy over undisclosed relationship
- JPMorgan shareholders support Dimon's dual roles in vote
- Gold charts point to fresh trouble ahead with eyes on $1,100/oz
- Sensex hits one-week low; doubts creep in after rally
- Omaxe raises $9 million in partially subscribed share sale
- Essar signs $1 billion financing deal with China
- HSBC says rupee better suited to stand USD strength
- Vodafone keeps Verizon payout to make up for European slump
